Diamond Hill Capital Management Inc. Sells 6,740,086 Shares of Pfizer Inc. $PFE

Diamond Hill Capital Management Inc. lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 38.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,924,267 shares of the biopharmaceutical company’s stock after selling 6,740,086 shares during the quarter. Diamond Hill Capital Management Inc.’s holdings in Pfizer were worth $278,350,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Plato Investment Management Ltd boosted its stake in Pfizer by 3.2% during the third quarter. Plato Investment Management Ltd now owns 219,270 shares of the biopharmaceutical company’s stock worth $5,544,000 after buying an additional 6,752 shares during the period. Palacios Wealth Management LLC boosted its holdings in shares of Pfizer by 15.7% in the third quarter. Palacios Wealth Management LLC now owns 23,692 shares of the biopharmaceutical company’s stock valued at $604,000 after purchasing an additional 3,223 shares during the period. Signature Estate & Investment Advisors LLC lifted its holdings in shares of Pfizer by 5.9% in the 3rd quarter. Signature Estate & Investment Advisors LLC now owns 24,326 shares of the biopharmaceutical company’s stock worth $620,000 after buying an additional 1,350 shares during the period. Lowe Brockenbrough & Co. Inc. grew its holdings in Pfizer by 8.4% during the 3rd quarter. Lowe Brockenbrough & Co. Inc. now owns 206,474 shares of the biopharmaceutical company’s stock worth $5,261,000 after acquiring an additional 15,992 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in Pfizer by 72.7% during the third quarter. Smartleaf Asset Management LLC now owns 32,688 shares of the biopharmaceutical company’s stock valued at $780,000 after buying an additional 13,755 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 earnings beat and GLP‑1 topline: Pfizer reported upside on revenue and EPS and released positive Phase 2b results for its lead GLP‑1 candidate (strong placebo‑adjusted weight loss), which helped lift sentiment around a new growth leg. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Positive Sentiment: Management outlines obesity strategy: Pfizer execs signaled the company is “back in the obesity race,” emphasizing development plans and commercialization intent after the encouraging GLP‑1 data. Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
• Positive Sentiment: FDA grants Priority Review for HYMPAVZI sBLA: The agency accepted a supplemental biologics license application to expand HYMPAVZI’s indication to pediatric and inhibitor populations in hemophilia, which could broaden revenue opportunity if approved. FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA
• Positive Sentiment: Mid‑stage obesity candidate complete: Pfizer announced completion of a mid‑stage trial for PF‑07976016, adding to its GLP‑1/obesity development cadence and potential registration pathway. Pfizer Completes Mid-Stage Trial of New Obesity Drug Candidate PF-07976016
• Positive Sentiment: Pipeline & M&A push into oncology and obesity: Analysts and coverage note Pfizer is lining up ~20 pivotal studies after ~ $9B of 2025 M&A, leaning on Seagen assets and AI tools to accelerate R&D — a multi‑year growth story. Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
• Positive Sentiment: Income investor attention: Pfizer appears on recent high‑yield dividend stock lists, which can support demand from yield‑focused investors. 3 High-Yield Dividend Stocks Perfect For Retirees
• Neutral Sentiment: Cost‑savings / affordability program: Pfizer launched a TrumpRx program offering discounts on ~30 medicines — positive for patient access and PR, but the near‑term financial impact is unclear. Pfizer Launches Cost-Savings Program on TrumpRx
• Neutral Sentiment: Analyst views mixed: Coverage notes cautious upside — bullish pipeline/AI drivers balanced by execution risk, time to commercialization, and competitive pressure in GLP‑1s. Pfizer Stock Forecast: Trending Analysts See Cautious Upside
• Negative Sentiment: Early‑stage trial halted: Pfizer paused an early‑stage study for PF‑07258669 in older adults, introducing a specific clinical risk that could require program adjustments. Pfizer Halts Early-Stage Trial for PF-07258669 in Older Adults

Pfizer Stock Performance

Shares of Pfizer stock opened at $27.24 on Friday. The firm has a market cap of $154.88 billion, a PE ratio of 20.03 and a beta of 0.47. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The business’s fifty day simple moving average is $25.61 and its 200-day simple moving average is $25.10.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. Pfizer’s revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.63 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 126.47%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PFE. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Bank of America reduced their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Scotiabank initiated coverage on Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Finally, BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.06.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.